Expert Review of Anticancer Therapy This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The PI3K signaling pathway; from normal lymphopoiesis to lymphoid malignancies
Expert Rev Anticancer Ther. 2024 May 1. doi: 10.1080/14737140.2024.2350629. Online ahead of print.ABSTRACTINTRODUCTION: As a vital mechanism of survival, lymphopoiesis requires the collaboration of different signaling molecules to orchestrate each step of cell development and maturation. The PI3K pathway is considerably involved in the maturation of lymphatic cells and therefore, its dysregulation can immensely affect human well-being and cause some of the most prevalent malignancies. As a result, studies that investigate this pathway could pave the way for a better understanding of the lymphopoiesis mechanisms, the undesi...
Source: Expert Review of Anticancer Therapy - May 1, 2024 Category: Cancer & Oncology Authors: Bahareh Kashani Zahra Zandi Atieh Pourbagheri-Sigaroodi Amir-Mohammad Yousefi Seyed H Ghaffari Davood Bashash Source Type: research

Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis
CONCLUSIONS: CT(A) and CT showed improved ORR compared with alternative regimens. CT(A) combined with PD-1/PD-L1 or PARP inhibitors significantly increased PCR rates. Comprehensive assessment of both ORR and safety indicated that CT(A) represents an optimal neoadjuvant therapy for HR+/HER2- breast cancer, whereas AI + CDK4/6 inhibitors rank solely behind chemotherapy.REGISTRATION: International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) registration number INPLASY202440092.PMID:38693054 | DOI:10.1080/14737140.2024.2350105 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - May 1, 2024 Category: Cancer & Oncology Authors: Ruiliang Chen Yushuai Yu Jie Zhang Chuangui Song Chuan Wang Source Type: research

The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer
Expert Rev Anticancer Ther. 2024 Apr 29. doi: 10.1080/14737140.2024.2349783. Online ahead of print.NO ABSTRACTPMID:38682638 | DOI:10.1080/14737140.2024.2349783 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - April 29, 2024 Category: Cancer & Oncology Authors: Gianluca Ingrosso Andrea Lancia Eleonora Festa Antonio Rosario Pisani Rita Bellavita Cynthia Aristei Beatrice Detti Source Type: research

Establishing biomarkers for soft tissue sarcomas
This article covers extensive recent research that has established novel potential biomarkers based on genomics, proteomics, and clinical characteristics. Validating and incorporating these biomarkers into clinical practice can improve prognosis, prediction of recurrence, and treatment response. Relevant literature was collected from PubMed, Scopus, and clinicaltrials.gov databases (November 2023).EXPERT OPINION: Currently, defining prognostic markers in soft tissue sarcomas remains challenging. More studies are required, especially to personalize treatment through advanced genetic profiling and analysis using individual t...
Source: Expert Review of Anticancer Therapy - April 29, 2024 Category: Cancer & Oncology Authors: Anna M Czarnecka Paulina Chmiel Piotr B łoński Piotr Rutkowski Source Type: research

The multidisciplinary management of locally advanced rectal cancer
Expert Rev Anticancer Ther. 2024 Apr 26. doi: 10.1080/14737140.2024.2349137. Online ahead of print.ABSTRACTINTRODUCTION: . The classic paradigm for the management of locally advanced rectal cancer (LARC) consists of (chemo)radiotherapy (C)RT), total mesorectal excision and adjuvant chemotherapy (CHT). At present, due to the high rate of distant metastasis (up to 30%), the total neoadjuvant therapy (TNT) with the administration of systemic CHT in the neoadjuvant setting has gained acceptance as standard of care.Our aim is to critically review current literature on LARC management and summarize the different approaches recen...
Source: Expert Review of Anticancer Therapy - April 27, 2024 Category: Cancer & Oncology Authors: Francesca De Felice Michelangelo Miccini Andrea Botticelli Michela Roberto Niccol ò Petrucciani Source Type: research

The survival effect of neoadjuvant therapy and neoadjuvant plus adjuvant therapy on pancreatic ductal adenocarcinoma patients with different TNM stages: a propensity score matching analysis based on the SEER database
CONCLUSIONS: In this retrospective cohort study, we demonstrated that patients harboring tumors in late TNM stages, including N2 resectable PDAC, might have better survival from NATAT, and that certain patients with M1 disease might still benefit from comprehensive systemic therapy and radical resection.PMID:38656796 | DOI:10.1080/14737140.2024.2347513 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - April 24, 2024 Category: Cancer & Oncology Authors: Hao Hu Yang Xu Qiang Zhang Yuan Gao Zhenyu Wu Source Type: research

Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review
Expert Rev Anticancer Ther. 2024 Apr 24:1-12. doi: 10.1080/14737140.2024.2346624. Online ahead of print.ABSTRACTINTRODUCTION: The incidence of primary liver cancer (PLC) has experienced a significant global increase, primarily attributed to the rise in hepatocellular carcinoma (HCC). Unfortunately, HCC is often diagnosed in advanced stages, leaving patients with limited treatment options. Therefore, transformation therapy is a crucial approach for long-term survival and radical resection in patients with advanced HCC. Conversion therapy has demonstrated promise in the treatment of advanced HCC. When integrated with the FOL...
Source: Expert Review of Anticancer Therapy - April 23, 2024 Category: Cancer & Oncology Authors: Suqi Zhu Yahan Yu Mingqi Yang Xin Liu Mingkai Lai Jieren Zhong Xiaoguang Zhao Ligong Lu Yanyan Liu Source Type: research